LGD-4033

LGD-4033 is a novel nonsteroidal, oral Selective Androgen Receptor Modulator that binds to the androgen receptor with high affinity and selectivity. It demonstrates anabolic activity in muscles, anti-resorptive and anabolic activity in bones and a robust selectivity for muscle and bone versus prostate and sebaceous glands. This compound has a slightly stronger physiological effect on test subjects than its counterpart MK-2866 (Osterine). Approximately 3% of test Subjects are Non-Responsive to LGD-4033. This compound has displayed a significant improvement in the general physiology of test subjects, including a marked increase in Lean muscle mass (improving the test subjects Body Mass Index). Physiological improvements of test subjects are considered dry with just slight water retention and a substantial improvement in the quality and density of muscle fiber tissue. The Pro version of LGD-4033 contains an "Absorb Core" base to improve bioavailability and to extend the half-life of the compound, making it one of the strongest and most efficient on the Research Compound market. LGD-4033 is slightly suppressive so a light PCT is required following administration of a course of this Compound. Recommended administration length is 8-12 weeks. Note: LGD-4033 is for sale on this site for Research Purposes only. By purchasing from this site, you are agreeing to use this compound for Research Purposes.